Pevonedistat

Chronic Myelomonocytic Leukemia

TakedaUNKNOWNPhase 3Active

BB

70/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 58/ 100
Competitive Position: 95/ 100

Competitive context

93 Active assets in the Chronic Myelomonocytic Leukemia cohort.

Asset / Sponsor	Phase	Rating
Venetoclax Servier Bio-Innovation LLC	Phase 2/3	BB
Azacitidine The University of Hong Kong	Phase 3	BB
Cyclosporin A Fred Hutchinson Cancer Center	Phase 2	BB
Melphalan City of Hope Medical Center	Phase 2	BB
Idarubicin Fred Hutchinson Cancer Center	Phase 3	BB

View all 50 →

Same molecule, other indications

Pevonedistat is also rated in:

acute myeloid leukemiaActive

BB

Indicative · Phase 3

66 / 100

myelodysplastic syndromeActive

B

Indicative · Phase 3

60 / 100

intrahepatic cholangiocarcinomaActive

CCC

Indicative · Phase 2

53 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.